Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL. Leonard JT, Kosaka Y, Malla P, LaTocha D, et al. Blood 2021;137:939-944.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Leonard JT, Kosaka Y, Malla P, LaTocha D, et al. Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL. Blood 2021;137:939-944.
PMID: 32898857